Published in Eur J Nucl Med Mol Imaging on March 19, 2014
A pretargeting system for tumor PET imaging and radioimmunotherapy. Front Pharmacol (2015) 0.84
Tumor immunotargeting using innovative radionuclides. Int J Mol Sci (2015) 0.82
Immuno-PET for Clinical Theranostic Approaches. Int J Mol Sci (2016) 0.80
Tumor and red bone marrow dosimetry: comparison of methods for prospective treatment planning in pretargeted radioimmunotherapy. EJNMMI Phys (2015) 0.80
Pharmacokinetics and Dosimetry Studies for Optimization of Pretargeted Radioimmunotherapy in CEA-Expressing Advanced Lung Cancer Patients. Front Med (Lausanne) (2015) 0.76
Challenges in nuclear medicine: innovative theranostic tools for personalized medicine. Front Med (Lausanne) (2014) 0.75
Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumors. Cancer Res (1990) 2.61
Long-term follow-up of renal function after peptide receptor radiation therapy with (90)Y-DOTA(0),Tyr(3)-octreotide and (177)Lu-DOTA(0), Tyr(3)-octreotate. J Nucl Med (2005) 1.78
Signal amplification in molecular imaging by pretargeting a multivalent, bispecific antibody. Nat Med (2005) 1.69
Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol (2000) 1.63
Patient-specific dosimetry in predicting renal toxicity with (90)Y-DOTATOC: relevance of kidney volume and dose rate in finding a dose-effect relationship. J Nucl Med (2005) 1.55
Stably tethered multifunctional structures of defined composition made by the dock and lock method for use in cancer targeting. Proc Natl Acad Sci U S A (2006) 1.50
Multifunctional antibodies by the Dock-and-Lock method for improved cancer imaging and therapy by pretargeting. J Nucl Med (2007) 1.35
Pretargeted molecular imaging and radioimmunotherapy. Theranostics (2012) 1.31
FcRn: the MHC class I-related receptor that is more than an IgG transporter. Immunol Today (1997) 1.30
Bone marrow dosimetry in peptide receptor radionuclide therapy with [177Lu-DOTA(0),Tyr(3)]octreotate. Eur J Nucl Med Mol Imaging (2009) 1.23
In vitro and in vivo targeting of radiolabeled monovalent and divalent haptens with dual specificity monoclonal antibody conjugates: enhanced divalent hapten affinity for cell-bound antibody conjugate. J Nucl Med (1989) 1.21
Bispecific antibody pretargeting PET (immunoPET) with an 124I-labeled hapten-peptide. J Nucl Med (2006) 1.18
Molecular advances in pretargeting radioimunotherapy with bispecific antibodies. Mol Cancer Ther (2002) 1.15
Prediction of myelotoxicity based on bone marrow radiation-absorbed dose: radioimmunotherapy studies using 90Y- and 177Lu-labeled J591 antibodies specific for prostate-specific membrane antigen. J Nucl Med (2005) 1.14
Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevalin radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. Crit Rev Oncol Hematol (2001) 1.14
Pretargeted immuno-positron emission tomography imaging of carcinoembryonic antigen-expressing tumors with a bispecific antibody and a 68Ga- and 18F-labeled hapten peptide in mice with human tumor xenografts. Mol Cancer Ther (2010) 1.13
Improved therapeutic results by pretargeted radioimmunotherapy of non-Hodgkin's lymphoma with a new recombinant, trivalent, anti-CD20, bispecific antibody. Cancer Res (2008) 1.07
Phase I/II radioimmunotherapy trial with iodine-131-labeled monoclonal antibody G250 in metastatic renal cell carcinoma. Clin Cancer Res (1998) 1.07
A universal pretargeting system for cancer detection and therapy using bispecific antibody. Cancer Res (2003) 1.05
Metastatic human colonic carcinoma: molecular imaging with pretargeted SPECT and PET in a mouse model. Radiology (2008) 1.04
Hematologic toxicity in radioimmunotherapy: dose-response relationships for I-131 labeled antibody therapy. Cancer Biother Radiopharm (2002) 1.01
Radioimmunotherapy with [131I]cG250 in patients with metastasized renal cell cancer: dosimetric analysis and immunologic response. Clin Cancer Res (2005) 0.97
Recombinant bispecific monoclonal antibodies prepared by the dock-and-lock strategy for pretargeted radioimmunotherapy. Semin Nucl Med (2010) 0.96
Pretargeted 177Lu radioimmunotherapy of carcinoembryonic antigen-expressing human colonic tumors in mice. J Nucl Med (2010) 0.94
Reagents and methods for PET using bispecific antibody pretargeting and 68Ga-radiolabeled bivalent hapten-peptide-chelate conjugates. J Nucl Med (2004) 0.93
Experimental studies on the role of antibody fragments in cancer radio-immunotherapy: Influence of radiation dose and dose rate on toxicity and anti-tumor efficacy. Int J Cancer (1998) 0.93
Pharmacokinetics and dosimetry studies for optimization of anti-carcinoembryonic antigen x anti-hapten bispecific antibody-mediated pretargeting of Iodine-131-labeled hapten in a phase I radioimmunotherapy trial. Clin Cancer Res (2003) 0.91
Practical determination of patient-specific marrow dose using radioactivity concentration in blood and body. J Nucl Med (1999) 0.90
Dosimetric analysis of 177Lu-cG250 radioimmunotherapy in renal cell carcinoma patients: correlation with myelotoxicity and pretherapeutic absorbed dose predictions based on 111In-cG250 imaging. J Nucl Med (2011) 0.90
Design and performance characteristics of an experimental cesium-137 irradiator to simulate internal radionuclide dose rate patterns. J Nucl Med (1997) 0.89
Pharmacokinetics and tumor localization of (111)in-labeled HuCC49DeltaC(H)2 in BALB/c mice and athymic murine colon carcinoma xenograft. Cancer Biother Radiopharm (2006) 0.88
Prediction of hematologic toxicity after radioimmunotherapy with (131)I-labeled anticarcinoembryonic antigen monoclonal antibodies. J Nucl Med (1999) 0.86
Development of an imaging-guided CEA-pretargeted radionuclide treatment of advanced colorectal cancer: first clinical results. Br J Cancer (2013) 0.84
Phase I/II clinical radioimmunotherapy with an iodine-131-labeled anti-carcinoembryonic antigen murine monoclonal antibody IgG. J Nucl Med (1997) 0.82
Quantitative immuno-SPECT monitoring of pretargeted radioimmunotherapy with a bispecific antibody in an intraperitoneal nude mouse model of human colon cancer. J Nucl Med (2012) 0.80
Software package for integrated data processing for internal dose assessment in nuclear medicine (SPRIND). Eur J Nucl Med Mol Imaging (2006) 0.80
1 World Congress on Ga-68 and Peptide Receptor Radionuclide Therapy (PRRNT), June 23-26, 2011, Zentralklinik Bad Berka, Germany. World J Nucl Med (2011) 0.79
Pretargeted immuno-PET of CEA-expressing intraperitoneal human colonic tumor xenografts: a new sensitive detection method. EJNMMI Res (2012) 0.78
FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0. Eur J Nucl Med Mol Imaging (2010) 7.82
Magnetic resonance tracking of dendritic cells in melanoma patients for monitoring of cellular therapy. Nat Biotechnol (2005) 5.80
Acute chemotherapy-induced cardiovascular changes in patients with testicular cancer. J Clin Oncol (2005) 3.29
The Netherlands protocol for standardisation and quantification of FDG whole body PET studies in multi-centre trials. Eur J Nucl Med Mol Imaging (2008) 3.24
Renal dosimetry in peptide radionuclide receptor therapy. Cancer Biother Radiopharm (2010) 3.23
A long-term prospective population pharmacokinetic study on imatinib plasma concentrations in GIST patients. Clin Cancer Res (2012) 2.95
Long-term outcome of biopsy-proven, frequently relapsing minimal-change nephrotic syndrome in children. Clin J Am Soc Nephrol (2009) 2.84
The alcohol-preferring P rat and animal models of excessive alcohol drinking. Addict Biol (2006) 2.82
FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging (2014) 2.79
Survival improvement in patients with medullary thyroid carcinoma who undergo pretargeted anti-carcinoembryonic-antigen radioimmunotherapy: a collaborative study with the French Endocrine Tumor Group. J Clin Oncol (2006) 2.79
Non-islet cell tumour-induced hypoglycaemia: a review of the literature including two new cases. Endocr Relat Cancer (2007) 2.63
Peritoneal carcinomatosis of colorectal origin: incidence and current treatment strategies. Ann Surg (2006) 2.62
Phenotypic and genotypic characterization of the Indiana University rat lines selectively bred for high and low alcohol preference. Behav Genet (2002) 2.56
Antibody pretargeting advances cancer radioimmunodetection and radioimmunotherapy. J Clin Oncol (2005) 2.55
Tumor targeting with radiolabeled alpha(v)beta(3) integrin binding peptides in a nude mouse model. Cancer Res (2002) 2.38
A novel method of 18F radiolabeling for PET. J Nucl Med (2009) 2.35
Hendra virus infection in a veterinarian. Med J Aust (2006) 2.32
Effective migration of antigen-pulsed dendritic cells to lymph nodes in melanoma patients is determined by their maturation state. Cancer Res (2003) 2.32
Beliefs and attitudes toward Buruli ulcer in Ghana. Am J Trop Med Hyg (2002) 2.30
Pallidal dysfunction drives a cerebellothalamic circuit into Parkinson tremor. Ann Neurol (2011) 2.30
Mycobacterium ulcerans disease. Bull World Health Organ (2005) 2.30
The EANM and SNMMI practice guideline for lymphoscintigraphy and sentinel node localization in breast cancer. Eur J Nucl Med Mol Imaging (2013) 2.25
Renal dosimetry: ready for biological effective dose? Cancer Biother Radiopharm (2010) 2.24
Gender differences in Parkinson's disease. J Neurol Neurosurg Psychiatry (2006) 2.23
Low dose oral desmopressin for nocturnal polyuria in patients with benign prostatic hyperplasia: a double-blind, placebo controlled, randomized study. J Urol (2010) 2.17
Fatigue and relating factors in high-risk breast cancer patients treated with adjuvant standard or high-dose chemotherapy: a longitudinal study. J Clin Oncol (2005) 2.14
The value of 18F-FDG PET/CT in diagnosing infectious endocarditis. Eur J Nucl Med Mol Imaging (2013) 2.13
Synthesis and comparison of 99mTc-enrofloxacin and 99mTc-ciprofloxacin. J Nucl Med (2004) 2.12
PAM4-reactive MUC1 is a biomarker for early pancreatic adenocarcinoma. Clin Cancer Res (2007) 2.06
Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin's lymphoma. J Clin Oncol (2003) 2.05
Indium-111-labeled girentuximab immunoSPECT as a diagnostic tool in clear cell renal cell carcinoma. Eur Urol (2013) 2.04
Gadopentetate dimeglumine and FDG uptake in liver metastases of colorectal carcinoma as determined with MR imaging and PET. Radiology (2005) 2.02
Non-invasive quantification of the beta cell mass by SPECT with ¹¹¹In-labelled exendin. Diabetologia (2014) 2.00
Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin's lymphoma: phase I/II clinical trial results. Clin Cancer Res (2004) 2.00
Risk factors for Buruli ulcer disease (Mycobacterium ulcerans Infection): results from a case-control study in Ghana. Clin Infect Dis (2005) 1.95
A prospective multicenter study on fever of unknown origin: the yield of a structured diagnostic protocol. Medicine (Baltimore) (2007) 1.87
PET/CT: panacea, redundancy, or something in between? J Nucl Med (2004) 1.86
Carbonic anhydrase IX in renal cell carcinoma: implications for prognosis, diagnosis, and therapy. Eur Urol (2010) 1.86
Histopathologic features of Mycobacterium ulcerans infection. Emerg Infect Dis (2003) 1.84
Imatinib mesylate for the treatment of gastrointestinal stromal tumours: best monitored with FDG PET. Nucl Med Commun (2004) 1.84
Phase II trial of carcinoembryonic antigen radioimmunotherapy with 131I-labetuzumab after salvage resection of colorectal metastases in the liver: five-year safety and efficacy results. J Clin Oncol (2005) 1.83
Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus. Arthritis Res Ther (2006) 1.82
Spatial resolution and sensitivity of the Inveon small-animal PET scanner. J Nucl Med (2009) 1.80
Trogocytosis of multiple B-cell surface markers by CD22 targeting with epratuzumab. Blood (2013) 1.78
Targeting, toxicity, and efficacy of 2-step, pretargeted radioimmunotherapy using a chimeric bispecific antibody and 131I-labeled bivalent hapten in a phase I optimization clinical trial. J Nucl Med (2006) 1.77
Improved 18F labeling of peptides with a fluoride-aluminum-chelate complex. Bioconjug Chem (2010) 1.76
Risk of new primary nonbreast cancers after breast cancer treatment: a Dutch population-based study. J Clin Oncol (2008) 1.76
Chemoimmunotherapy reinduction with epratuzumab in children with acute lymphoblastic leukemia in marrow relapse: a Children's Oncology Group Pilot Study. J Clin Oncol (2008) 1.75
18F-FDG PET reduces unnecessary hemithyroidectomies for thyroid nodules with inconclusive cytologic results. J Nucl Med (2006) 1.75
A re-examination of radioimmunotherapy in the treatment of non-Hodgkin lymphoma: prospects for dual-targeted antibody/radioantibody therapy. Blood (2009) 1.72
Recent advances in animal models of alcohol craving and relapse. Pharmacol Biochem Behav (2004) 1.72
Imaging of inflammation by PET, conventional scintigraphy, and other imaging techniques. J Nucl Med (2010) 1.71
Intravenously administered short interfering RNA accumulates in the kidney and selectively suppresses gene function in renal proximal tubules. Drug Metab Dispos (2006) 1.71
Radioimmunotherapy of non-Hodgkin's lymphoma with 90Y-DOTA humanized anti-CD22 IgG (90Y-Epratuzumab): do tumor targeting and dosimetry predict therapeutic response? J Nucl Med (2003) 1.71
Signal amplification in molecular imaging by pretargeting a multivalent, bispecific antibody. Nat Med (2005) 1.69
18F-FLT PET during radiotherapy or chemoradiotherapy in head and neck squamous cell carcinoma is an early predictor of outcome. J Nucl Med (2013) 1.69
Improved targeting of the alpha(v)beta (3) integrin by multimerisation of RGD peptides. Eur J Nucl Med Mol Imaging (2006) 1.66
Intracranial self-administration of ethanol within the ventral tegmental area of male Wistar rats: evidence for involvement of dopamine neurons. J Neurosci (2004) 1.65
Dual-targeting immunotherapy of lymphoma: potent cytotoxicity of anti-CD20/CD74 bispecific antibodies in mantle cell and other lymphomas. Blood (2012) 1.63
Feasibility of withholding antibiotics in selected febrile neutropenic cancer patients. J Clin Oncol (2005) 1.62
Radioimmunotherapy is an effective adjuvant treatment after cytoreductive surgery of experimental colonic peritoneal carcinomatosis. J Nucl Med (2006) 1.61
99mTc-labeled interleukin 8 for the scintigraphic detection of infection and inflammation: first clinical evaluation. J Nucl Med (2007) 1.61
The prognostic effect of the number of histologically examined axillary lymph nodes in breast cancer: stage migration or age association? Ann Surg Oncol (2006) 1.58
Ethanol increases glutamate neurotransmission in the posterior ventral tegmental area of female wistar rats. Alcohol Clin Exp Res (2011) 1.58
Epratuzumab for patients with moderate to severe flaring SLE: health-related quality of life outcomes and corticosteroid use in the randomized controlled ALLEVIATE trials and extension study SL0006. Rheumatology (Oxford) (2013) 1.58
Pretargeting with bispecific anti-renal cell carcinoma x anti-DTPA(In) antibody in 3 RCC models. J Nucl Med (2005) 1.57
The insulin-like growth factor system and sarcomas. J Pathol (2009) 1.57